What We Know About the Risks While research specific to eating disorders is limited, the National Eating Disorders Association (NEDA) and eating disorder professionals have identified several concerning patterns: Risk of Triggering or Worsening Eating Disorders There is growing evidence that GLP-1s may trigger new eating disorders or worsen existing ones
This approach takes advantage of epitalon's effects on pineal gland function and sleep-related hormone regulation
It may also decrease glucose-stimulated insulin secretion (GSIS), potentially leading to neonatal glucose dysregulation and associated risks
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM
In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Bossart et al., 2022)